GlassScriptPhysician profile
Thomas R Johnson
NPI 1518938927
$11,924.94
in general payments reported to CMS, 2019-2025
57 companies · $2,443 in 2025
The $2,443 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,137 · 2020: $565 · 2021: $145 · 2022: $1,368 · 2023: $1,492 · 2024: $3,774 · 2025: $2,443.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,970 · Long Term Medical Supply Or Device Loan: $1,530 · Education: $210.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,969.79 |
| Long Term Medical Supply Or Device Loan | $1,529.72 |
| Education | $209.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,485.54 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $705.00 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Astrazeneca Pharmaceuticals LP | $638.21 | 2019-2025 | Imfinzi, Calquence, Lynparza |
| Amgen INC. | $582.53 | 2019-2023 | Kyprolis, Nplate, Xgeva |
| Pfizer INC. | $580.44 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $570.84 | 2019-2025 | Opdivo, Opdualag |
| Janssen Biotech, INC. | $524.72 | 2019-2025 | Darzalex, Tecvayli, Talvey |
| Astellas Pharma US INC | $486.42 | 2022-2025 | Xospata, Vyloy, Xtandi |
| Celgene Corporation | $437.87 | 2020-2025 | Reblozyl, Pomalyst, Opdualag |
| Incyte Corporation | $419.13 | 2019-2025 | Monjuvi, Pemazyre, Jakafi |
| Genentech USA, INC. | $406.59 | 2019-2025 | Polivy, Venclexta, Columvi |
| Regeneron Healthcare Solutions, INC. | $371.39 | 2019-2025 | Libtayo |
| Eisai INC. | $334.60 | 2019-2025 | |
| Genzyme Corporation | $316.95 | 2019-2025 | |
| Daiichi Sankyo INC. | $303.79 | 2019-2025 | Enhertu, Datroway, Injectafer |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.